TSC22D3 and melanoma: This in situ GC secretion is related to the failure of immunotherapy in preclinical models of melanoma and in patients with melanoma.261 In NSCLC patients, scRNA-seq has indicated an association between the expression of TSC22D3 in tumor-infiltrating DCs and peripheral blood monocytes.